John Rim, the company’s former executive vice-president, has been named its new president and CEO.
Samsung Biologics announced on Dec. 16, 2020 that John Rim, the company’s former executive vice-president, has been named its new president and CEO.
Rim has more than 30 years of experience in the biopharmaceutical industry and previously held senior global leadership roles at Genentech/Roche and Astellas Pharmaceuticals after starting his career at Booz, Allen & Hamilton as a management consultant, Samsung said in a company press release.
“I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade,” said Rim in the press release. “This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business execution by great people whom I will have the privilege to lead as CEO.”
